Caty Ebel Bitoun
Pfizer
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Caty Ebel Bitoun.
European Urology | 2008
Christopher R. Chapple; Vik Khullar; Zahava Gabriel; Dominic Muston; Caty Ebel Bitoun; David Weinstein
CONTEXT Antimuscarinic agents are currently the first-line pharmacotherapy for overactive bladder. OBJECTIVES A systematic review published in 2005 was updated, including data on a newly licensed antimuscarinic (fesoterodine). The primary aim of this study was to systematically review evidence on the efficacy of licensed administration of antimuscarinic treatments in overactive bladder from randomised controlled trials. Secondary aims were to review evidence on tolerability and safety and health-related quality of life (HRQL). EVIDENCE ACQUISITION All relevant data sources from randomised controlled trials were searched, and two independent reviewers considered publications for inclusion and extracted relevant data. Meta-analysis was used to pool efficacy, tolerability, safety, and HRQL outcomes by treatment. Efficacy was measured by continent days, mean voided volume, urgency episodes, and micturition frequency. Tolerability and safety were measured by means of adverse event and withdrawal rates. HRQL was measured by various instruments. EVIDENCE SYNTHESIS An additional 1118 references were retrieved with data on 83 studies extracted. Antimuscarinics were found to be more effective than placebo. Tolerability was good; few of the antimuscarinics were found to have significantly higher withdrawal rates in comparison to placebo. No serious adverse event for any product was statistically significant compared to placebo. Dry mouth (mild, moderate, severe) was the most commonly reported adverse event (29.6% on treatment vs 7.9% on placebo), followed by pruritus (15.4% on treatment vs 5.2% on placebo). Improvements were seen in HRQL with treatment by darifenacin, fesoterodine, oxybutynin transdermal delivery system, propiverine extended release (ER), solifenacin, tolterodine ER and immediate release, and trospium. Limitations of the study include restrictions on the types of patients typically included in overactive bladder trials and topics that have not been adequately addressed in the current antimuscarinic literature. CONCLUSIONS Antimuscarinics are efficacious, safe, and well-tolerated treatments that improve HRQL. Profiles of each drug and dosage differ and should be considered in making treatment choices.
Journal of the American Geriatrics Society | 2013
Adrian Wagg; Vik Khullar; Daniela Marschall-Kehrel; Martin C. Michel; Matthias Oelke; Amanda Darekar; Caty Ebel Bitoun; David Weinstein; Ian Osterloh
To assess the efficacy and safety of flexible‐dose fesoterodine in elderly adults with overactive bladder (OAB).
Neurourology and Urodynamics | 2014
Vik Khullar; Chris C. Sexton; Christine Thompson; Ian Milsom; Caty Ebel Bitoun; Karin S. Coyne
To evaluate the relationship between body mass index (BMI) and urinary incontinence (UI) in adults ≥40 from the United States, United Kingdom, and Sweden.
Neurourology and Urodynamics | 2014
Adrian Wagg; Vik Khullar; Martin C. Michel; Matthias Oelke; Amanda Darekar; Caty Ebel Bitoun
To assess the long‐term safety, tolerability, and efficacy of flexible‐dose fesoterodine in elderly patients with OAB.
BJUI | 2013
Vik Khullar; Linda Cardozo; Con Kelleher; Timothy L. Hall; John Ryan; Caty Ebel Bitoun; Amanda Darekar; Daniel Arumi; Adrian Wagg
To determine the course of overactive bladder (OAB) symptoms after 4 weeks of no treatment following a 12‐week study of the efficacy and safety of flexible‐dose fesoterodine in patients with OAB who were enrolled in the UK healthcare system. There are limited data available on the natural time course of OAB symptoms after the cessation of treatment.
International Urogynecology Journal | 2012
Linda Cardozo; Timothy L. Hall; John Ryan; Caty Ebel Bitoun; Imran Kausar; Amanda Darekar; Adrian Wagg
ics.org | 2011
Adrian Wagg; Vik Khullar; Daniela Marschall-Kehrel; Martin C. Michel; Matthias Oelke; Amanda Darekar; Caty Ebel Bitoun; Ian Osterloh; David Weinstein
ics.org | 2010
David Castro-Diaz; Pilar Miranda; Francisco Sanchez-Ballester; Daniel Arumi; Isabel Lizarraga; Caty Ebel Bitoun
The Journal of Urology | 2012
Vik Khullar; Karin S. Coyne; Chris C. Sexton; Zoe Kopp; Caty Ebel Bitoun; Ian Milsom
ics.org | 2011
Linda Cardozo; John Ryan; Timothy L. Hall; Caty Ebel Bitoun; Imran Kausar; Amanda Darekar; Adrian Wagg; Laurence Whelan; Vik Khullar